Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716384 | 0.89 | ALDH1A1 (0.52) | POLBGAADRD3ALDH1A1MEN1 | |
| SCHEMBL151627 | 0.85 | ALDH1A1 (0.52) | POLBGAADRD3ALDH1A1MEN1 | |
| SCHEMBL3520495 | 0.84 | POLB (0.48) | POLBLCKGAAALDH1A1 | |
| SCHEMBL716014 | 0.83 | MEN1 (0.55) | POLBGAADRD3ALDH1A1MEN1 | |
| SCHEMBL10962715 | 0.82 | POLB (0.47) | POLBLCKGAAALDH1A1 | |
| SCHEMBL712716 | 0.82 | LCK (0.48) | POLBLCKGAAALDH1A1 | |
| SCHEMBL13718713 | 0.81 | HRH3 (0.40) | HRH3POLBGAAMAPTDRD3 | |
| SCHEMBL14370175 | 0.81 | HRH3 (0.43) | HRH3MAPTDRD3ALDH1A1PYCR1 | |
| SCHEMBL13938792 | 0.79 | HRH3 (0.49) | HRH3MAPTDRD3ALDH1A1NPC1 | |
| SCHEMBL148920 | 0.78 | MAOB (0.49) | POLBGAADRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354529-B2 | Polyamine derivative and polyol derivative | BASF SE (DE) | 2013-01-15 | — | — | US | disclosed |
| EP-2511274-A2 | Polyamine derivative | BASF SE (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-2484677-A1 | Polyamine derivative | BASF SE (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-20120053270-A1 | POLYAMINE DERIVATIVE AND POLYOL DERIVATIVE | MITA NARUYOSHI (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8076478-B2 | Stabilizer; photostability, heat resistance, ozone resistance, oxidation resistance, electromagnetic resistance | BASF SE (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20080230743-A1 | Polyamine Derivative and Polyol Derivative | CIBA CORPORATION | 2008-09-25 | — | — | US | disclosed |
| EP-1840127-A1 | POLYAMINE DERIVATIVE AND POLYOL DERIVATIVE | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053270-A1 | POLYAMINE DERIVATIVE AND POLYOL DERIVATIVE | H1-0, H1-3, NPM1 | HRH3 30/4885POLB 548/4885LCK 2455/4885 |
| US-20080230743-A1 | Polyamine Derivative and Polyol Derivative | H1-0, H1-3, H1-2 | HRH3 62/4885POLB 145/4885LCK 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.